×
About 11,347,816 results

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
https://www.scripps.edu/_files/pdfs/news-and-events/The D614G mutation in the SARS-CoV-2 spike protein reduces S1.pdf

SARS coronavirus 2 (SARS-CoV-2) isolates encoding a D614G mutation in the viral spike (S) protein predominate over time in locales where it is found, implying that this change enhances viral transmission. We therefore compared the functional properties of the S proteins with aspartic acid (SD614) and glycine (SG614) at residue 614. We observed that retroviruses pseudotyped with SG614 infect...

COVID-19 in Racial and Ethnic Minority Groups
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html
CDC

The effects of COVID-19 on the health of racial and ethnic minority groups is still emerging; however, current data suggest a disproportionate burden of illness and death among racial and ethnic minority groups. A recent CDC MMWR report included race and ethnicity data from 580 patients hospitalized with lab-confirmed COVID-19 found that 45% of individuals for whom race or ethnicity data was av...

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
https://www.onclive.com/view/robust-data-and-multivariate-analyses-support-cabazitaxel-as-a-standard-of-care-in-mcrpc

May 30th, 2020

COSMIC-021 Data Affirm Activity of Cabozantinib/Atezolizumab in mCRPC
https://www.onclive.com/view/cosmic021-data-affirm-activity-of-cabozantinibatezolizumab-in-mcrpc

Jun 7th, 2020

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma
https://www.onclive.com/view/dr-richardson-on-phase-1-data-with-cc92480-in-multiple-myeloma

May 31st, 2020

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL
https://www.onclive.com/view/dr-wang-on-correlative-data-from-the-zuma2-trial-in-mcl

May 31st, 2020

Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk
https://onlinelibrary.wiley.com/doi/10.1111/joim.13070

Early data from Wuhan, China, show that patients with COVID‐19 are typically male, aged 40 to 60 years, and about one‐third have comorbidities. Moreover, of 138 COVID‐19 patients hospitalized in Wuhan and treated in an intensive care unit (ICU), 25% had cardiovascular disease and 58% hypertension; the respective figures for non‐ICU‐treated COVID‐19 patients were10% and 22% [1]. Based on these e...

CURE Drug Repurposing Collaboratory
https://c-path.org/programs/cdrc/

The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). CDRC, in partnership with the FDA-NCATS CURE ID* platform, is a dedicated initiative designed to ca...

High Temperature and High Humidity Reduce the Transmission of COVID-19
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551767

With the ongoing global pandemic of COVID-19, a question is whether the coming summer in the northern hemisphere will reduce the transmission intensity of COVID-19 with increased humidity and temperature. In this paper, we investigate this problem using the data from the cases with symptom-onset dates from January 19 to February 10, 2020 for 100 Chinese cities, and cases with confirmed dates fr...

Effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187824/

The coronavirus disease 2019 (COVID-19) pandemic is the defining global health crisis of our time and the greatest challenge facing the world. Meteorological parameters are reportedly crucial factors affecting respiratory infectious disease epidemics; however, the effect of meteorological parameters on COVID-19 remains controversial. This study investigated the effects of temperature and relati...

The role of climate during the COVID‐19 epidemic in New South Wales, Australia
https://onlinelibrary.wiley.com/doi/full/10.1111/tbed.13631

Previous research has identified a relationship between climate and occurrence of SARS‐CoV and MERS‐CoV cases, information that can be used to reduce the risk of infection. Using COVID‐19 notification and postcode data from New South Wales, Australia during the exponential phase of the epidemic in 2020, we used time series analysis to investigate the relationship between 749 cases of locally ac...

Yale University Research, Clinical, & Data Driven Responses to COVID-19
https://covid.yale.edu/

Scientists, scholars, and physicians across Yale are actively engaged in research, innovation, and clinical efforts to combat COVID-19 (2019 Novel Coronavirus). This website seeks to facilitate collaboration at Yale and across the world by transparently communicating our research progress and patient care initiatives.

SARS-CoV-2 and Nervous System - Neurological Manifestations in Patients With COVID-19: A Systematic Review
https://www.neurores.org/index.php/neurores/article/view/602/580

Coronavirus (CoV) is a virus infectious disease with a considerable spectrum of clinical presentations. Symptoms ranged from asymptomatic infection to severe pneumonia that may lead to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and several clinical complications. Neurologic symptoms related to CoV have been described recently in the literature. The relationship between SARS-Co...

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study
https://link.springer.com/article/10.1007/s10072-020-04519-x

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 ye...

Molecular Interaction Studies of Garlic Active Compound for Lowering Down the Blood Pressure Using Bioinformatics Approach
https://poseidon01.ssrn.com/delivery.php?ID=161070001067087065090123082019004123120047030012065075094104116097003025100005073120049062054045104022006125120000089011121103123011053034003086087013087104109014010021050031124076088081104092025085101100106119126007121103125095101004097084079094099087&EXT=pdf

High Blood pressure is regarded as “silent killer” because person may not feel that something is happening wrong in the body, but it can quietly cause damage that can threaten health. Non-pharmacological approaches, such as alternative / complementary medicine have potential to reduce cardiovascular risk factor such as high blood pressure. Garlic supplements i.e. phytochemicals plays an imp...

Expert Perspective on ASCO20 Quality Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200237/full/

Jul 6th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 23rd, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Expert Perspectives on the ASCO20 Plenary Session
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200236/full/

Jul 5th, 2020 - The JAVELIN Bladder 100 study (LBA1) investigated the efficacy of maintenance avelumab following platinum-based chemotherapy compared to best supportive care for patients with metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared to 14.3 months with best supportive care. These data are practice changing, and the degree of benefit to this a...

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 24th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Sci...